Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn&apos;s Disease: Results from the Phase 3 VIVID-1 study

Inflammatory Bowel Disease

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Gastroenterology

Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G

doi: 10.1053/j.gastro.2025.02.033

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Further Publications

Comparative Improvement in Health-Related Quality of Life with Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis

Am J Gastroenterol

Olivera PA, Parks ML, Zubiaurre I, Peyrin-Biroulet L, Lasa JS, Targownik LE

doi: 10.14309/ajg.0000000000003333

Inflammatory Bowel Disease

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

Lancet Gastroenterol Hepatol

Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S

doi: 10.1016/S2468-1253(25)00017-2

Inflammatory Bowel Disease

Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program

Inflamm Bowel Dis

Sands BE, Dubinsky MC, Kotze PG, Vermeire S, Panaccione R, Long MD, Woolcott JC, Wu J, McDonnell A, Goetsch M, Bananis E, Yarur AJ

doi: 10.1093/ibd/izaf036

Inflammatory Bowel Disease

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Clin Gastroenterol Hepatol

Colombel JF, Lacerda AP, Irving PM, Panaccione R, Reinisch W, Rieder F, Steinlauf A, Schwartz D, Feng T, Dubcenco E, Anyanwu SI, Laroux FS, Cunneen C, Powell N

doi: 10.1016/j.cgh.2024.08.032

Inflammatory Bowel Disease

Evaluation of Crohn's Disease Activity: Validation of a Segmental Simple Ultrasound Score in a Multicenter Study

Inflamm Bowel Dis

Ripollés T, Poza J, Martínez-Pérez MJ, Suarez Ferrer C, Blanc E, Paredes JM

doi: 10.1093/ibd/izae213

Inflammatory Bowel Disease

Biologic switch timing and risk of infection in patients with ulcerative colitis/Crohn's disease: a retrospective study

Clin Gastroenterol Hepatol

Kruger AJ, Dormont F, Capit N, Schilsky S, Roberts A, Lin Y, Badalamenti S, Wiekowski M, Bewtra M, Colombel JF

doi: 10.1016/j.cgh.2025.01.028

Inflammatory Bowel Disease

Changes in endoscopic activity and classification of lesions with panenteric capsule endoscopy in patients treated for Crohn's disease - a prospective blinded comparison with ileocolonoscopy, faecal calprotectin and C-reactive protein

J Crohns Colitis

Brodersen JB, Kjeldsen J, Juel MA, Knudsen T, Rafaelsen SR, Jensen MD

doi: 10.1093/ecco-jcc/jjae124

Related content

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Comparative Improvement in Health-Related Quality of Life with Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Evaluation of Crohn's Disease Activity: Validation of a Segmental Simple Ultrasound Score in a Multicenter Study

Biologic switch timing and risk of infection in patients with ulcerative colitis/Crohn's disease: a retrospective study

Changes in endoscopic activity and classification of lesions with panenteric capsule endoscopy in patients treated for Crohn's disease - a prospective blinded comparison with ileocolonoscopy, faecal calprotectin and C-reactive protein